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OBJECTIVES: Buprenorphine/naloxone combination (BUP/NAL) has been 
available in a film formulation since 2010 for the treatment of opioid 
dependence. A clinical trial showed that patients preferred the film to tablet 
formulation. Insurance claims data extracted from MarketScan Medicaid 
database were analyzed to compare patient persistence and health care costs 
between the two formulations. METHODS: Patients initiating treatment with 
BUP/NAL after the launch of film (September 2010) were classified in two groups 
according to formulation of initial prescription: film or tablet. Time to treatment 
discontinuation and monthly health care costs by treatment phase (before 
treatment, initiation period, during treatment, discontinuation period, after 
discontinuation and reinitiation period) were compared between the two groups, 
adjusting on baseline characteristics (demographics, comorbidities, treatment, 
and resource utilization before treatment). RESULTS: Analysis included 450 
patients initially treated with film and 1127 with tablet, followed over 6.3 and 8.0 
months on average respectively. Of those treated with tablet, 17.8% of patients 
switched to film. The average dose at initiation was 16 mg in both groups. 
Kaplan-Meier estimates of the probability of persistence 200 days were 59.11% 
and 51.46% in the film and tablet groups respectively. The hazard ratio for 
treatment discontinuation with film versus tablet, adjusted on baseline 
characteristics, was 0.72 (p=0.02). Monthly costs were highest around the time of 
treatment initiation, switch and discontinuation. Monthly costs during 
treatment were $418.76 for patients treated with film and $477.66 with tablet 
(p=0.1561). Monthly costs after treatment discontinuation were 40% lower among 
patients treated with film (p=0.0354). CONCLUSIONS: Patients treated with 
BUP/NAL film appear to have a lower probability of early treatment 
discontinuation. Treatment with the film formulation may generate cost savings 
since costs around discontinuation are relatively high, and costs after treatment 
discontinuation were found to be lower among patient previously treated with 
film.  
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OBJECTIVES: Given bipolar disorder (BPD) and schizophrenia impose a 
significant burden in the workplace, this study evaluated the annual costs 
among US employees with BPD or schizophrenia. METHODS: Analysis of 2001-
2012 HCMS database from subjects with BPD/schizophrenia diagnostic claims 
and ≥12 months follow-up after their index-date and subjects without 
BPD/schizophrenia (controls). Index date was defined as: (i) initial claim date for 
subjects with BPD or schizophrenia and (ii) average of BPD and schizophrenia 
index date by year for controls. Inflation-adjusted annual costs including 
medical, Rx, sick leave (SL), short-term disability (STD) and workers’ 
compensation (WC) were compared between cohorts using two-part regression, 
controlling for confounders. RESULTS: Total annual costs among BPD subjects 
(n=5299) were higher compared to controls (n=653,707) in 2001 (+$8573) and 2011 
(+$9547), respectively. Differences were significant (P<0.005) in all costs 
categories in 2001 (Medical=$4701, Rx=$2252, SL=$391, STD=$762, and WC=$461) 
and in 2011(Medical=$6147, Rx=$2552, SL=$208 and STD=$413). Total costs, 
medical costs and Rx costs were higher among schizophrenia (n=391) subjects 
than controls in the years 2001 (+$8,812, +$6549 and +$2119), and 2011 (+$7772, 
+$5191, and +$2630), respectively. In 2001, BPD subjects’ costs were $239 lower 
than schizophrenia despite significantly higher STD (+$649) and WC (+$666) 
costs. In 2011, however, subjects with BPD incurred greater costs than those with 
schizophrenia ($1775; P>0.05). From years 2001-2011, BPD subjects’ medical costs 
increased (+$1950) and STD costs decreased (-$473). Consistent decreases in STD 
costs were observed among the BPD subjects since 2006, and direct medical costs 
as a percent of total costs increased from 78.9%-86.7% for BPD subjects and from 
75.2%-78.8% for controls. CONCLUSIONS: In this employer database, STD costs 
have become marginally lower since 2006. However, medical costs (e.g., 
ER/inpatient visits) among these patient populations still remain high, 
suggesting the need for therapeutic options with a lower medical cost burden.  
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OBJECTIVES: To evaluate the impact of metabolic comorbidities on health care 
resource utilization and costs in hospitalized patients with schizophrenia. 
METHODS: A retrospective observational study was conducted utilizing data 
from the Premier Perspective Database™ from October 1, 2010 to May 31, 2012. 
Patients with an admitting primary or secondary diagnosis of schizophrenia 
during the study period were eligible for inclusion. Patients were classified as 
having 0, 1, 2, or 3+ metabolic comorbidities based upon diagnoses of diabetes 
mellitus, hyperglycemia, hypertension, dyslipidemia, coronary heart disease, 
ischemic heart disease, or cardiovascular disease (CVD) during their index 
hospitalization. Generalized linear models were used to compare costs across 
the 4 comorbidity cohorts (0, 1, 2, 3+). Logistic regressions were used to compare 
the likelihood of readmission and the likelihood of death among the comorbidity 
cohorts. RESULTS: A total of 57,506 patients met all inclusion criteria; 33.9% with 
0 comorbidities, 26.7% with 1 comorbidity, 19.9% with 2 comorbidities, and 19.4% 
with 3 or more comorbidities. Among patients with comorbidities, 57% had 
hypertension, 28% had diabetes, 30% had hyperlipidemia, 10% had 
coronary/ischemic heart disease, 4% had CVD, and 2% had hyperglycemia. As the 
number of comorbidities increased from 0 to 3+, there were increases in medical 
costs ($9,619 to $13,111; P<0.0001), pharmacy costs ($501 to $1,540; P<0.0001), and 
total costs ($10,120 to $14,651; P<0.0001). Patients with a higher number of 
comorbidities were more likely to have a readmission for any cause (9% to 13%; 
P<0.0001) and die during their index hospitalization (0.3% to 2%; P<0.0727), 
although increases in mortality were not statistically significant. CONCLUSIONS: 
A high prevalence of metabolic comorbidities was found in this study population 
of hospitalized schizophrenia patients. An increase in the number of metabolic 
comorbidities had adverse clinical and economic consequences, including 
increased costs and readmission rates.  
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OBJECTIVES: To estimate the indirect costs for community-dwelling Texas 
residents with schizophrenia. METHODS: This was a retrospective database 
study using Medical Expenditure Panel Survey (MEPS) data from 2005 to 2008. 
The proportion of the total national indirect costs for ‘all mental illnesses’ (based 
on DSM IV criteria) that were attributable to Texas patients was estimated and 
this ratio was applied to the national indirect costs for schizophrenia (ICD9 code 
of 295) to estimate costs attributable to Texas patients. Categories for indirect 
costs included: restricted activity-associated costs (based on number of work 
days missed), reduced employment costs (based on difference in wages for 
patients with versus without schizophrenia), premature mortality costs (based 
on percentage of patients who commit suicide times discounted wages lost), and 
caregivers’ costs (based on days of work missed by an unpaid caregiver). These 
estimates were adjusted to 2008 dollars and summed to obtain the 2005-2008 
total 4-year indirect costs for patients with schizophrenia in Texas. All analyses 
were carried out using the ‘survey’ procedure of SAS in order to account for the 
complex sample design of MEPS. RESULTS: For community-dwelling patients 
with schizophrenia in Texas (weighted n = 153,872 patient years), the mean 
indirect costs per patient year were about $17,000. The estimated productivity 
cost per patient-year due to reduced employment, premature mortality, 
restricted activity and caregivers’ cost was $16,572, $215, $67, and $50 
respectively. The total indirect costs for patients with schizophrenia in this 
Texas population between 2005 and 2008 amounted to about $2.6 billion, or 
about $650 million per year. These estimates did not include costs for homeless, 
institutionalized, or incarcerated patients. CONCLUSIONS: This study highlights 
the high financial burden of indirect costs for community-dwelling patients with 
schizophrenia, most of which were due to reduced employment.  
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OBJECTIVES: Schizophrenia-related costs in the US have been estimated at over 
$60 billion annually. Although state Medicaid plans cover a large percent of the 
population with schizophrenia, other non-Medicaid state budgets are 
responsible for covering the costs for patients who are incarcerated or admitted 
to state-operated inpatient mental health facilities. The purpose of the study was 
to estimate the annual direct and indirect costs for Texas Medicaid patients with 
schizophrenia. METHODS: Direct costs were estimated from the perspective of 
the state of Texas as payer using data from 2006-2008 adjusted to 2008 US 
dollars. Direct Texas Medicaid costs were extracted from claims files (about 9,000 
patients per year). State-operated inpatient mental health facility costs were 
provided in aggregated form by the Texas Department of State Health Services. 
Data from the Bureau of Justice Statistics and recent literature were used to 
estimate incarceration costs. Medical Expenditure Panel Survey data from 2005-
2008 were used to estimate indirect costs per patient-year. Direct costs to the 
patient (e.g. travel and unreimbursed expenses) were not captured. RESULTS: 
The schizophrenia-related mean annual per patient cost was estimated at 
$31,511 - direct and indirect costs were $14,607 (46.3%) and $16,904 (53.7%), 
respectively. Direct costs to Medicaid, state-operated inpatient mental health 
facilities, and jails accounted for 31.6%, 1.1%, and 13.6% of total costs, 
respectively. Most of the indirect costs (98%) were due to morbidity-associated 
productivity losses, with the remaining small portion were due to mortality-
associated productivity losses (early death/suicide), and unpaid caregivers’ lost 
productivity. CONCLUSIONS: This was the first study that estimated both direct 
and indirect costs of schizophrenia in the Texas Medicaid population. Direct 
medical costs paid by Medicaid accounted for only about one-third of total costs. 
These cost estimates may help health care providers and policymakers better 
understand the economic burden of schizophrenia.  
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OBJECTIVES: Opioid poisoning has increased substantially over the past decade, 
and has been associated with increases in opioid prescribing. This has been 
accompanied by intervention efforts aimed at preventing and reversing opioid 
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poisoning through naloxone prescription programs. Understanding the economic 
burden of opioid poisoning can help inform these efforts and highlight the need 
for further interventions to attenuate current trends. The main objectives of this 
study were to quantify the economic burden of opioid poisoning, estimate the 
cost per poisoning event, and to quantify costs of opioid poisoning for specific 
prescription opioids in the United States. METHODS: A cost-of-illness approach 
was used. Direct costs related to hospitalization and ED visits and estimates  
for mortality and prevalence were obtained from nationally representative 
databases. Other sources of direct costs were obtained from the literature. 
Indirect costs included absenteeism and premature mortality costs, and  
were measured using the human capital method. One-way and probabilistic 
sensitivity analyses were used to test assumptions. RESULTS: Opioid poisoning 
resulted in an economic burden of approximately $20.4 billion in 2009. Eighty-
nine percent was attributed to productivity losses, of which 98% was  
from premature mortality. Approximately $2.2 billion were attributed to direct 
medical costs. Costs for heroin and prescription opioid poisoning were estimated 
to be $4.6 billion and $15.9 billion, respectively. The cost per poisoning event  
was estimated to be $37,274 for all opioids. The cost per poisoning event for 
heroin and prescription opioids was $33,793 and $38,541, respectively. The three 
prescription opioids with the greatest poisoning costs were hydrocodone, 
oxycodone, and methadone. CONCLUSIONS: Opioid poisoning results in  
a significant economic burden to society. Costs related to mortality account  
for the majority of the costs. Interventions that prevent or reverse opioid 
poisoning can have significant impacts on cost, especially where death is 
prevented.  
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OBJECTIVES: To identify relapse in schizophrenia and the main cost drivers  
of relapse using a claims-based algorithm. METHODS: Multistate Medicaid data 
(1997–2010) were used to identify adults with schizophrenia receiving atypical 
antipsychotics (AAPs). The first schizophrenia diagnosis following AAP initiation 
was defined as the index date. Baseline weekly cost was assessed during the  
12 months before the index date, and weekly costs were calculated for ≥2 years 
post index. An algorithm was developed to identify relapse episodes based on 
weeks associated with high cost increase from baseline and high absolute 
weekly cost. Resource use and costs of relapsers during baseline and relapse 
episodes were compared using incidence rate ratios (IRRs) and bootstrap 
methods. No adjustment was made for multiplicity. RESULTS: 9,793 relapsers 
were identified, with a mean of 9 relapse episodes per patient. Duration of 
relapse episodes decreased over time, with a mean(median) duration of 34(4) 
weeks for the first and 8(1) weeks for remaining episodes. Compared with 
baseline, resource utilization during relapse episodes was significantly greater in 
pharmacy, outpatient, and institutional visits (hospitalizations and emergency 
room visits), with IRRs ranging from 1.9–2.4 (all p<.0001). Correspondingly, 
relapse was associated with a mean (95% CI) cost increase of $2459($2384–
$2539)—nearly 6 times larger than mean (median) weekly baseline maintenance 
cost of $425($148). Institutional visits characterized most (53%) of the relapse 
episode incremental costs, with hospitalizations (excluding mental institute 
inpatient admissions) representing 36%. CONCLUSIONS: Relapses in 
schizophrenia patients were associated with cost on average 6 times higher than 
the median maintenance costs. Institutional visits characterized most of the cost 
increase.  
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OBJECTIVES: This study aimed to assess the clinical and economic burden of 
schizophrenia in the U.S. veteran population. METHODS: Patients diagnosed 
with schizophrenia were included in a retrospective study conducted using the 
Veterans Health Administration (VHA) Medical SAS Datasets. The study period 
was from January 1, 2006 to May 31, 2012. Health care resource utilization and 
costs were assessed in the 12-month follow-up period. Descriptive statistics were 
calculated as means ± standard deviation (SD) and percentages to measure 
treatment, cost, and utilization distribution in the sample. RESULTS: For VHA 
patients diagnosed with schizophrenia (n=59,691), the most common 
comorbidities were counseling not otherwise specified (21.25%), other specified 
counseling (19.42%) and unspecified essential hypertension (18.90%). 52.56% of 
patients were prescribed oral anti-psychotic therapy (OAT) and 2.43% were 
prescribed long-acting anti-psychotic therapy (LAT). The most commonly 
prescribed medications after diagnosis were risperidone (20.66%), simvastatin 
(17.58%), quetiapine (17.21%), omeprazole (15.16%), lisinopril (14.79%) and aspirin 
(13.58%). Percentages of inpatient (38.13%), emergency room (ER) (35.19%), 
physician office (98.86%), and outpatient visits (99.08%) were also calculated. 
Patient expenditures were found to be $18,162 (SD= $65,948) for inpatient, $517 
(SD=$1,333) for ER, $10,366 (SD=$14,243) for physician office and $11,074 
(SD=$14,923) for outpatient visits. CONCLUSIONS: Results suggest that 
risperidone was the most frequently prescribed medication after a diagnosis of 
schizophrenia. However, more research is needed to better understand adverse 
events and side effects of risperidone.  
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OBJECTIVES: To examine the treatment, clinical and economic burden of mental 
disorders in the U.S. veteran population. METHODS: Patients diagnosed with 
mental disorders were studied in a retrospective study (1/1/2006-5/31/2012) using 
the Veterans Health Administration Medical SAS Datasets. The mental disorders 
studied included mood disorder, attention deficit hyperactivity disorder, panic 
disorder, post-traumatic stress disorder, obsessive-compulsive disorder, 
generalized anxiety disorder, personality disorder, depression, anxiety, suicide, 
and intentional injuries. Using the initial mental disorder diagnosis date as the 
index date, patients were required to have at least 1 year of continuous health 
plan benefits pre- and post-index date. Health care resource utilization and costs 
were assessed for the 12-month follow-up period. Descriptive statistics were 
calculated as means ± standard deviation (SD) and percentages to measure 
treatment, cost, and utilization distribution in the sample. RESULTS: Among 
patients identified with mental disorders (n=1,644,214), 48.60% were diagnosed 
with depression, 46.56% with mood disorders, and 21.57% with intentional 
injuries. The most common comorbidities were unspecified essential 
hypertension (21.07%), counseling not otherwise specified (18.35%), and other 
specified counseling (15.92%). 38.88% of patients were prescribed anti-depressant 
treatment, and 15.99% anti-cholinergic treatment. The most commonly 
prescribed medications were simvastatin (20.09%), lisinopril (15.36%), 
omeprazole (14.49%), citalopram hydrobromide (14.26%), and 
hydrochlorothiazide (8.47%). Percentages of inpatient (18.90%), emergency room 
(ER) (27.50%), physician office (99.51%), and outpatient visits (99.77%) were also 
calculated. Patient expenditures were found to be $6,893 (SD= $36,727) for 
inpatient, $312 (SD=$1,085) for ER, $7,249 (SD= $11,523) for physician office and 
$7,820 (SD=$12,262) for outpatient visits. CONCLUSIONS: Depression and mood 
disorders were the most prevalent mental disorders. Anti-depressant drugs were 
the most commonly prescribed medication type during the 60 days after mental 
disorder diagnosis. Mental disorders were associated with high health care 
utilizations, and created a significant cost burden on the health care system.  
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OBJECTIVES: Post-traumatic stress disorder (PTSD) is a type of anxiety disorder that 
occurs after experiencing a traumatic event, and can lead to severe impairment of a 
patient’s daily life. The study aims to assess the clinical and economic burden of 
PTSD in the U.S. veteran population. METHODS: Patients diagnosed with PTSD 
(International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-
CM]: 309.81) were selected from the Veterans Health Administration (VHA) database 
(October 1, 2006-May 31, 2010). The first observed diagnosis date was defined as the 
index date. Continuous medical and pharmacy benefits were required 12-months 
pre- and post-index date. The top ten most common comorbidities were calculated 
for the 12-month baseline period. The top ten treatments were calculated for 60 
days post-index date. Health care resource utilization (inpatient, outpatient, office, 
emergency room [ER] visits), and costs (inpatient, outpatient, ER, pharmacy total 
costs) were assessed for the 12-month follow-up period. Descriptive statistics were 
calculated as means ± standard deviation (SD) and percentages to measure 
treatment, cost, and utilization distribution in the sample. RESULTS: For VHA PTSD 
patients (n=488,770), the most common comorbidities were essential hypertension 
(19.07%) and depressive disorder (13.42%.%). 50.43% of patients were prescribed 
anti-depressant treatment, and 15.35% anti-cholinergics treatment. The most 
commonly prescribed medications were citalopram hydrobromide (17.94%), 
simvastatin (15.47%), omeprazole (12.26%), lisinopril (11.92%), and trazodone 
(11.30%). Percentages of inpatient (16.10%), ER (22.76%), physician office (99.86%), 
and outpatient visits (99.89%) were also calculated. Patient expenditures were found 
to be $5,240 (SD= $29,382) for inpatient, $264 (SD=$822) for ER, $8,437 (SD= $10,803) 
for physician office and $8,926 (SD=$11,443) for outpatient visits. CONCLUSIONS: 
Results suggest that hypertension and depressive disorder are the most common 
comorbidities during the baseline period. Anti-depressant prescriptions were most 
prevalent during the 2-month follow-up period. PTSD was associated with high 
inpatient and ER visit rates, translating into a high cost burden.  
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OBJECTIVES: To determine trends in Attention Deficit Hyperactivity Disorder 
(ADHD) medication use and expenditures in the US from 2000 to 2010. 
METHODS: This was a retrospective cross-sectional analysis of the household 
component of the Medical Expenditure Panel Survey (MEPS) data from 2000 to 
2010 (using the full-year consolidated data files and prescribed medicines files) 
involving all ADHD patients (International Classification of Disease 9th revision 
[ICD-9] code 314) on any FDA approved ADHD medication. Outcome measures 
were ADHD medication utilization and cost (adjusted to 2010 dollars). Since 
